

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. Initial Public Offer of equity shares on the main board of the Stock Exchanges in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").



(Please scan the QR code to view the RHP)

INNOVA CAPTAB LIMITED

Our Company was incorporated in Mumbai, Maharashtra, as 'Haran Health Care Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 3, 2005, issued by the Registrar of Companies, Maharashtra at Mumbai (the "RoC"). Thereafter, pursuant to a resolution passed by our Shareholders in the extraordinary general meeting held on December 26, 2009, the name of our Company was changed from 'Haran Health Care Private Limited' to 'Innova Captab Private Limited', and consequently, a fresh certificate of incorporation dated February 2, 2010, was issued by the RoC to our Company. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed by our Shareholders in the extraordinary general meeting held on July 12, 2018, and consequently, the name of our Company was changed to our present name, 'Innova Captab Limited', and a fresh certificate of incorporation dated July 26, 2018, was issued by the RoC to our Company. For details of changes in the name and the registered office address of our Company, see History and Certain Corporate Matters on page 220 of the red herring prospectus dated December 14, 2023 filed with RoC.

Registered Office: 601, Proxima, Plot No. 19, Sector 30 A, Vashi, Navi Mumbai, Maharashtra 400 705, India; Telephone: 91 22 2554 2095

Corporate Identity Number: U24240MH2005PLC150371; Website: www.innovacaptab.com

Corporate Office: Second Floor, SCO No. 301, Sector 9, Panchkula, Haryana 134 109, India; Contact Person: Neelharika Shukla, Company Secretary and Compliance Officer; Telephone: +91 172 4194500; Email: investors@innovacaptab.com

THE PROMOTERS OF OUR COMPANY ARE MANOJ KUMAR LOHARIWALA AND VINAY KUMAR LOHARIWALA

INITIAL PUBLIC OFFERING OF UP TO (a) EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹(a) PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹(a) PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹(a) MILLION ("OFFER"), THE OFFER COMPRISSES OF A FRESH ISSUE OF UP TO (a) EQUITY SHARES AGGREGATING UP TO ₹3,200.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO ₹5,580.357 EQUITY SHARES ("OFFERED SHARES") AGGREGATING UP TO ₹(a) MILLION. THE OFFER WILL CONSTITUTE (a) % OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

| NAME OF SELLING SHAREHOLDER | TYPE | DETAILS OF THE OFFER FOR SALE BY THE SELLING SHAREHOLDERS | WEIGHTED AVERAGE COST OF ACQUISITION PER EQUITY SHARE (IN ₹)* |
|-----------------------------|----------|--|---|
| MANOJ KUMAR LOHARIWALA | PROMOTER | NUMBER OF SHARES OFFERED / AMOUNT (₹ IN MILLION) Up to 1,953.125 Equity Shares aggregating up to ₹(a) million | 2.32 |
| VINAY KUMAR LOHARIWALA | PROMOTER | Up to 1,953.125 Equity Shares aggregating up to ₹(a) million | 15.20 |
| GIAN PARKASH AGGARWAL | OTHER | Up to 1,674.107 Equity Shares aggregating up to ₹(a) million | 2.26 |

*As certified by N B T & Co, Chartered Accountants, by way of their certificate dated December 19, 2023.

*The price of acquisition, have been adjusted for the sub-division in the face value of the equity shares of the Company from ₹100 each to ₹10 each pursuant to a resolution of the Shareholders dated April 4, 2022, as applicable.

We are an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.

The Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations.

• QIB Portion: Not more than 50% of the Offer • Non-Institutional Portion: Not less than 15% of the Offer • Retail Portion: Not less than 35% of the Offer

PRICE BAND: ₹ 426 TO ₹ 448 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH

THE FLOOR PRICE IS 42.60 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 44.80 TIMES THE FACE VALUE OF THE EQUITY SHARES

THE PRICE/EARNINGS RATIO BASED ON DILUTED EPS FOR FISCAL 2023 AT THE FLOOR PRICE IS 30.08 TIMES AND AT THE CAP PRICE IS 31.64 TIMES

BIDS CAN BE MADE FOR A MINIMUM OF 33 EQUITY SHARES AND IN MULTIPLES OF 33 EQUITY SHARES THEREAFTER

In accordance with the recommendation of Committee of Independent Directors of our Company, pursuant to their resolution dated December 15, 2023, the above provided price band is justified based on quantitative factors/ KPIs disclosed in the 'Basis for the Offer Price' section of the RHP vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), disclosed in 'Basis for the Offer Price' section on pages 116 to 122 of the RHP.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER.

RISKS TO INVESTORS:

- We depend on a limited number of CDMO customers. Any reduction in the number of CDMO customers and adverse developments or inability to enter into or maintain relationships with these CDMO customers could have an adverse effect on our business, results of operations and financial condition. Our revenue from operations from CDMO business from our top ten customers and such revenue as a percentage of our operations is set forth below:

| Revenue from Operations | Fiscal 2021 | | Fiscal 2022 | | Fiscal 2023 | | Three Months ended June 30, 2023 | |
|-------------------------|-------------|---|-------------|---|-------------|---|----------------------------------|---|
| | ₹ million | % of revenue from operations from CDMO business | ₹ million | % of revenue from operations from CDMO business | ₹ million | % of revenue from operations from CDMO business | ₹ million | % of revenue from operations from CDMO business |
| Top Ten Customers | 2,022.01 | 54.52% | 3,341.18 | 48.66% | 3,825.40 | 56.29% | 1,136.63 | 68.39% |

- A portion of the proceeds from this Offer will not be available to us. The proceeds from the Offer for Sale will be remitted to the Selling Shareholders and our Company will not benefit from such proceeds.
- We are dependent on the import of raw materials from China, China SEZ and Hong Kong. This exposes us to political, economic and social conditions in greater China.

| Restated Consolidated | For the year ended March 31, | | | For the three months ended June 30, 2023 |
|--|------------------------------|--------|--------|--|
| | 2021 | 2022 | 2023 | |
| Imported raw materials from China, China SEZ and Hong Kong as a percentage of our cost of imported raw materials | 91.85% | 90.03% | 75.41% | 100% |
| Imported raw materials from China, China SEZ and Hong Kong as a percentage of total raw material | 13.11% | 12.28% | 6.18% | 1.15% |

- Our business is capital intensive. Any insufficient cash flows from our operations or inability to borrow to meet our working capital requirements it may materially and adversely affect our business and results of operations. As of October 31, 2023, our sanctioned working capital facilities amounted to ₹2,650.00 million on a restated consolidated basis and our amount outstanding under our working capital facilities was ₹1,585.53 million on such date. We intend to utilise ₹720.00 million (as part of the Net Proceeds) towards funding our incremental working capital requirements in Fiscal 2023 and Fiscal 2024.
- Our Restated Consolidated Financial Information are not comparable on a period-to-period basis and to any future financial results that we may prepare and further, our Pro Forma Condensed Consolidated Financial Information are unaudited and have not been prepared in accordance with generally accepted accounting principles including accounting standard and therefore, is subject to change and may not give an accurate picture of our factual results of operations or financial condition.
- We operate in a market that is highly competitive. Our competition for formulation and branded generic products is with pharmaceutical companies and other generic product suppliers in India and other jurisdictions.
- We have recently acquired Sharon, and do not yet know whether we will achieve the expected benefits from such acquisition, which could materially adversely affect our business, results

of operation, cash flows and financial condition.

- We have two manufacturing facilities in Baddi, Himachal Pradesh. Our business is dependent and will continue to depend on our manufacturing facilities, and we are subject to certain risks in our manufacturing process such as the breakdown or failure of equipment, industrial accidents, severe weather conditions and natural disasters.
- Failure to comply with the quality requirements and technical specifications prescribed by our customers may lead to loss of business from such customers and could negatively impact our business, results of operations and financial condition, including cancellation of existing and future orders which may expose us to warranty claims.
- Our funding requirements and proposed deployment of the Net Proceeds are based on management estimates and may be subject to change based on various factors, some of which are beyond our control.
- We have incurred significant capital expenditure during the last three Fiscal Years and the three months ended June 30, 2023.

(₹ in million)

| Restated Consolidated | As at March 31, | | | As at June 30, 2023 |
|-----------------------|-----------------|--------|--------|---------------------|
| | 2021 | 2022 | 2023 | |
| Capital expenditure | 110.63 | 768.24 | 260.99 | 143.90 |

- Average cost of acquisition of Equity Shares held by the Selling Shareholders ranges from ₹2.36 to ₹15.20 per Equity Share and Offer Price at higher end of the Price Band is ₹448 per Equity Share.
- Weighted Average Return on Net Worth for past three Fiscals i.e. 2023, 2022 and 2021 is 26.48%
- Details of weighted average cost of acquisition of all Equity Shares transacted in last three years, eighteen months and one year immediately preceding the date of the RHP

| Period | Weighted average cost of acquisition (WACA)* (in ₹) | Cap Price is 'x' times the weighted average cost of acquisition | Range of acquisition (Lowest Price-Highest Price) (in ₹) |
|------------------|---|---|--|
| Last one year | 403.37 | 1.11 | 354.00 – 448.00 |
| Last 18 months | 403.37 | 1.11 | 354.00 – 448.00 |
| Last three years | 336.56 | 1.33 | 166.67 – 448.00 |

*As certified by the N B T & Co, Chartered Accountants, by way of their certificate dated December 19, 2023.

- Weighted average cost of acquisition, floor price and cap price

| Past transactions | Weighted average cost of acquisition (in ₹) | Floor Price (₹ 426) | Cap Price (₹ 448) |
|--|---|---------------------|-------------------|
| Since there are no such primary issuances or secondary transactions as set out in (a) and (b) above, details of the price per share based on the last five primary or secondary transactions as detailed in (c) are set out below: | | | |
| - Primary issuances | 21.01 | 20.28 times | 21.33 times |
| - Secondary transactions | 288.43 | 1.48 times | 1.55 times |

- The two BRLMs associated with the Offer have handled 72 public issues in the past three years, out of which 19 issues closed below the offer price on listing date.

| Name of BRLMs | Total Issues | Issues Closed Below IPO Price on Listing Date |
|------------------------------------|--------------|---|
| ICICI Securities Limited* | 30 | 10 |
| JM Financial Limited* | 24 | 3 |
| Common issues handled by the BRLMs | 18 | 6 |
| Total | 72 | 19 |

*Issues handled where there were no common BRLMs.

Continued on next page...

